HomeCompareBDR vs JNJ

BDR vs JNJ: Dividend Comparison 2026

BDR yields 655.74% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDR wins by $531184.32M in total portfolio value
10 years
BDR
BDR
● Live price
655.74%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$531184.35M
Annual income
$408,606,309,899.83
Full BDR calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — BDR vs JNJ

📍 BDR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDRJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDR + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDR pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDR
Annual income on $10K today (after 15% tax)
$55,737.70/yr
After 10yr DRIP, annual income (after tax)
$347,315,363,414.86/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, BDR beats the other by $347,315,359,377.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDR + JNJ for your $10,000?

BDR: 50%JNJ: 50%
100% JNJ50/50100% BDR
Portfolio after 10yr
$265592.19M
Annual income
$204,303,157,324.85/yr
Blended yield
76.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BDR
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDR buys
0
JNJ buys
0
No recent congressional trades found for BDR or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDRJNJ
Forward yield655.74%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$531184.35M$30.5K
Annual income after 10y$408,606,309,899.83$4,749.88
Total dividends collected$521134.98M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BDR vs JNJ ($10,000, DRIP)

YearBDR PortfolioBDR Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$76,274$65,573.77$10,594$274.49+$65.7KBDR
2$549,048$467,435.39$11,294$360.69+$537.8KBDR
3$3,732,138$3,144,656.22$12,133$476.91+$3.72MBDR
4$23,970,675$19,977,287.04$13,156$635.42+$23.96MBDR
5$145,564,116$119,915,494.45$14,432$854.61+$145.55MBDR
6$836,312,314$680,558,709.22$16,056$1,162.76+$836.30MBDR
7$4,549,085,040$3,654,230,864.88$18,175$1,604.53+$4549.07MBDR
8$23,444,186,795$18,576,665,801.85$21,009$2,252.68+$23444.17MBDR
9$114,558,920,290$89,473,640,419.13$24,911$3,229.73+$114558.90MBDR
10$531,184,354,610$408,606,309,899.83$30,458$4,749.88+$531184.32MBDR

BDR vs JNJ: Complete Analysis 2026

BDRStock

Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television (TV) signal encoding, transcoding, digital transport, and broadband product solutions in the United States. It offers encoders/transcoders, such as 4K/ultra-high definition, high definition and standard definition, MPEG-2, MPEG-4/H.264, and HEVC/H.265 capable encoders and transcoders; and QPSK and 8PSK, and QAM transcoders. The company also provides NXG IP digital video processing and headend products, including IPTV format conversions and simulcast use cases. In addition, it offers coax distribution products comprising broadband amplifiers, directional taps, splitters, and wall outlets; coax distribution products are either mounted on exterior utility poles or encased in pedestals, vaults, or other security devices in cable television systems; distribution system is enclosed within the walls of the building or added to an existing structure using various techniques to hide the coax cable and devices in SMB systems; and non-passive devices for signal distributed from the headend is of sufficient strength when it arrives at its final destination to provide audio/video images. Further, the company provides CPE products consisting of Android-based IPTV set top boxes. Additionally, it offers digital modulation products, such as Aircastertm ATSC, QAM, and IP trans-modulator series of products allow the user to create a line up from off-air and/or cable feeds for coax IP distribution; Edge QAM devices that accept Ethernet input and capture MPEG over IP transport streams, decrypt service provider conditional access or content protection, and insert proprietary conditional access; DOCSIS data products; service level agreements and services; and analog modulation, fiber, and miscellaneous products and services, as well as test and measurement instruments, and contract manufacturing services. The company was founded in 1950 and is headquartered in Old Bridge, New Jersey.

Full BDR Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BDR vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDR vs SCHDBDR vs JEPIBDR vs OBDR vs KOBDR vs MAINBDR vs ABBVBDR vs MRKBDR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.